M
Miriam Puttini
Researcher at University of Milano-Bicocca
Publications - 8
Citations - 925
Miriam Puttini is an academic researcher from University of Milano-Bicocca. The author has contributed to research in topics: Tyrosine kinase & Proto-oncogene tyrosine-protein kinase Src. The author has an hindex of 7, co-authored 8 publications receiving 851 citations. Previous affiliations of Miriam Puttini include National Institutes of Health & University of Geneva.
Papers
More filters
Journal ArticleDOI
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
Carlo Gambacorti-Passerini,Laura Antolini,Franois Xavier Mahon,François Guilhot,Michael W. Deininger,Carmen Fava,Arnon Nagler,Chiara Maria Della Casa,Enrica Morra,Elisabetta Abruzzese,Anna D'Emilio,Fabio Stagno,Philipp le Coutre,Rafael Hurtado-Monroy,Valeria Santini,Bruno Martino,Fabrizio Pane,Andrea Piccin,P Giraldo,Sarit Assouline,Muheez A. Durosinmi,O. C. Leeksma,Enrico Pogliani,Miriam Puttini,Eun-Jung Jang,Josy Reiffers,Maria Grazia Valsecchi,Dong-Wook Kim +27 more
TL;DR: In this study, CML-related deaths were uncommon in CML patients who were in CCyR 2 years after starting imatinib, and survival was not statistically significantly different from that of the general population.
Journal ArticleDOI
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
Miriam Puttini,Addolorata Coluccia,Frank Boschelli,Loredana Cleris,Edoardo Marchesi,Arianna Donella-Deana,Shaheen Ahmed,Sara Redaelli,Rocco Piazza,Vera Magistroni,Federica Andreoni,Leonardo Scapozza,Franca Formelli,Carlo Gambacorti-Passerini +13 more
TL;DR: SKI-606 proved to be an active inhibitor of Bcr-Abl in several chronic myelogenous leukemia cell lines and transfectants, with IC(50) values in the low nanomolar range, 1 to 2 logs lower than those obtained with imatinib.
Journal ArticleDOI
Inhibition of RET tyrosine kinase by SU5416.
Luca Mologni,Elisa Sala,Sara Cazzaniga,Roberta Rostagno,Thomas Kuoni,Miriam Puttini,Jenny Bain,Loredana Cleris,Sara Redaelli,Barbara Riva,Franca Formelli,Leonardo Scapozza,Carlo Gambacorti-Passerini +12 more
TL;DR: It is found that SU5416 inhibits RET with similar potency, both in cell-free assays and in cells, thus causing proliferation arrest in oncogenic RET-transfected cells and in papillary thyroid carcinoma (PTC) cells expressing the RET/PTC1 oncogene, but not in RET-negative control cells.
Journal ArticleDOI
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma
Annamaria Galietta,Annamaria Galietta,Annamaria Galietta,Rosalind H. Gunby,Sara Redaelli,Paola Stano,Cristiana Carniti,Angela Bachi,Philip W. Tucker,Carmen J. Tartari,Carmen J. Tartari,Ching Jung Huang,Emanuela Colombo,Karen Pulford,Miriam Puttini,Rocco Piazza,Holger Ruchatz,Antonello Villa,Arianna Donella-Deana,Oriano Marin,Danilo Perrotti,Carlo Gambacorti-Passerini,Carlo Gambacorti-Passerini +22 more
TL;DR: Results identify PSF as a novel NPM/ALK-binding protein and substrate, and suggest that PSF function may be perturbed in NPM /ALK-transformed cells.
Journal ArticleDOI
Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Rosalind H. Gunby,Elisa Sala,Carmen J Tartari,Miriam Puttini,Carlo Gambacorti-Passerini,Luca Mologni +5 more
TL;DR: The PTKs known to be expressed as FTKs in cancer are reviewed and the strategies for molecularly targeting these FTKS in anti-cancer therapy are reviewed.